Skip to main content
Caplight Logo









DefEYE, Inc.

DefEYE, Inc.

Private
Sarasota, FloridaHealthcare & Life Scienceshttps://defeye.com/

Last Round

Seed

Oct 22, 2025

Est. Valuation

$31M

Total Funding Raised

$12M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

DefEYE, Inc. is a biotechnology company that develops and commercializes decellularized biologic solutions, including amniotic barrier membranes, for the management of ocular surface diseases and surgical recovery.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical Devices

Business Model

B2B

Customer Profile

Hardware Sales

AI Layer

Non-AI

Keywords

ophthalmic biologicsamniotic membrane graftregenerative medicineocular surface repairbiologicsallograftbiotechbuy-and-billhuman tissue productsurgical biomaterialswound healingophthalmology supply

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

DefEYE, Inc. Comparables

Compare DefEYE, Inc. with similar companies based on industry and business-model similarity.

DefEYE, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Merakris Therapeutics
87%
Oculus Biologics
86%
Skye Biologics Holdings
85%

DefEYE, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedOct 22, 2025

Key People

Founding team and executive leadership

Rob Sambursky

Chief Executive Officer

Executive Team

DefEYE, Inc. Investors

Notable investors and investment history

DefEYE, Inc. investors
InvestorRounds
ExSight VenturesSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 3, 2026

    Grew 23% QoQ, from 13 to 16 employees.

  • Jul 30, 2026

    Grew 45% QoQ, from 11 to 16 employees.

DefEYE, Inc. Filings

Explore SEC and related filing metadata, where available.

DefEYE, Inc. filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about DefEYE, Inc.'s valuation, stock price, and market status.

Is DefEYE, Inc. a public or private company?

DefEYE, Inc. is a private company.

What is the current stock price of DefEYE, Inc.?

DefEYE, Inc. is a private company with no public stock price. Caplight tracks DefEYE, Inc.'s secondary market activity and provides MarketPrice™ estimates to Caplight users.

How much is DefEYE, Inc. worth (valuation)?

DefEYE, Inc.'s valuation is estimated at $31.0M based on funding round data.

Can I buy DefEYE, Inc. stock?

DefEYE, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was DefEYE, Inc.'s last funding round?

DefEYE, Inc.'s most recent funding round was Seed on October 22, 2025.

Who are the main investors in DefEYE, Inc.?

Key investors in DefEYE, Inc. include ExSight Ventures.

Will DefEYE, Inc. IPO soon?

No public IPO plans have been announced for DefEYE, Inc..

How can I track DefEYE, Inc. secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor DefEYE, Inc.'s secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSarasota, Florida
Employee Range15
Year Founded2025
Last FundingOct 22, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?